Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use

Fig. 1

Clinical characteristics of Oncotype DX users between 2004 and 2015. A Oncotype DX usage rate among patients with ER+HER2−, ER+HER2+, and all breast cancer subtypes. B Oncotype DX usage rate among the four stages of breast cancer. C Oncotype DX usage rate between patients with lymph node-positive and negative breast cancer. D Oncotype DX usage rate among different patient age groups. Usage rates were calculated based on the total number of patients within each indicated patient subgroup

Back to article page